MELBOURNE, Australia, July 30, 2026
Amplia Therapeutics announced the online publication of comprehensive preclinical findings evaluating narmafotinib in pancreatic cancer models. The research, led by Professor Paul Timpson and colleagues at the Garvan Institute of Medical Research, provides new insights into the mechanisms through which narmafotinib may exert anti-cancer effects. Across multiple preclinical models, the investigational therapy demonstrated reduced tumor fibrosis, enhanced anti-tumor activity when combined with chemotherapy, decreased cancer dissemination and metastatic spread, and downregulation of genes associated with chemotherapy resistance. The published findings further strengthen the biological rationale for combining narmafotinib with chemotherapy and support Amplia’s ongoing clinical development program in pancreatic cancer.
Preclinical Research Demonstrates Multiple Anti-Tumor Mechanisms
The newly published study investigated narmafotinib across several preclinical pancreatic cancer models to better understand its potential therapeutic activity. Researchers observed a significant reduction in tumor fibrosis, a hallmark of pancreatic cancer that can limit drug penetration and contribute to disease progression. In combination with chemotherapy, narmafotinib enhanced anti-tumor activity compared with chemotherapy alone, while also reducing cancer dissemination and metastatic spread. The study further identified downregulation of genes linked to chemotherapy resistance, suggesting the investigational therapy may help improve treatment responsiveness in this aggressive cancer.
Enrollment Nears Completion While Cardiac Safety Profile Remains Favorable
According to Amplia, the publication provides additional scientific validation for the company’s strategy of evaluating narmafotinib alongside standard chemotherapy. The findings expand understanding of the drug candidate’s multifaceted mechanisms of action and support its continued clinical investigation in pancreatic cancer. Chief Executive Officer and Managing Director Dr. Chris Burns stated that the research conducted by Professor Timpson’s team over several years strengthens the scientific rationale for narmafotinib’s clinical development while offering deeper insight into how the therapy may address the complex biology of pancreatic cancer.
Advertisement
Findings Support Ongoing Pancreatic Cancer Development Program
Although the results remain preclinical and require confirmation in human clinical studies, the publication adds important mechanistic evidence supporting narmafotinib’s development. Pancreatic cancer remains one of the most difficult cancers to treat because of extensive tumor fibrosis, high metastatic potential, and frequent chemotherapy resistance. By demonstrating potential benefits across each of these disease characteristics, the study provides additional support for Amplia’s ongoing efforts to evaluate narmafotinib as a combination therapy aimed at improving treatment outcomes for patients with pancreatic cancer.
Source: Amplia Therapeutics press release
